
Evolus (EOLS) Stock
Medical aesthetics company selling cosmetic treatments to clinics. Here's the price, business snapshot, and what's worth knowing about Evolus in November 2026.
Evolus, Inc. (EOLS) is a US-based aesthetics company best known for Jeuveau, a prescription neuromodulator used in cosmetic treatments. The business model centres on physician adoption, direct-to-practice sales, and international growth via partners. Investors should note revenue depends heavily on product demand, marketing effectiveness and reimbursement climates in target markets. The company competes with larger, established players in medical aesthetics and must balance promotional investment with margin progression. Key attractions include exposure to the growing elective aesthetic market and potential for incremental international expansion; key risks include product competition, regulatory changes, variability in consumer spending, and the typical volatility of small-cap stocks. Evolus’s market cap is modest, which can magnify price swings. This summary is educational and not personalised advice — investors should carry out their own research, consider diversification, and be aware that past performance does not predict future returns.
Evolus (EOLS) Stock Forecast
Analyst price target, next 12 months
$19.20
+185.7% vs today's $6.72
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Evolus have a consensus 12-month target of $19.20, above the current price of $6.72.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Evolus' stock with a target price of $19.2, indicating significant growth potential.
Financial Health
Evolus is performing well with strong revenue and cash flow, indicating good business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Elective Market Growth
Rising demand for non‑surgical cosmetic procedures supports long‑term market potential, though revenues can ebb with consumer confidence.
Commercial Execution
Physician adoption and targeted marketing are key near‑term levers; execution risk matters for small, growth‑oriented firms.
International Opportunity
Selective global expansion via partners could broaden reach, but regulatory and distribution challenges add uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.